yttrium Y-90 DOTA-peptide-Lym-1

yttrium Y 90 DOTA-peptide-Lym-1 is a radioimmunotherapeutic conjugate developed primarily by researchers at the University of California, Davis, for the treatment of B-cell malignancies. It consists of the murine monoclonal antibody Lym-1, which targets a polymorphic epitope on the HLA-DR10 beta subunit highly expressed in B-cell non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL). The antibody is conjugated to the high-energy beta-emitting radioisotope yttrium-90 (Y-90) via the macrocyclic chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and a specific peptide linker (often a tripeptide such as glycyl-tyrosyl-lysine). The inclusion of the peptide linker was a strategic modification designed to enhance the pharmacokinetic profile by facilitating faster blood clearance and significantly reducing radiation-induced toxicity to the liver compared to the standard DOTA-Lym-1 construct. Once bound to the target malignant cells, the Y-90 isotope delivers localized ionizing radiation, leading to DNA damage and apoptosis in both the targeted cells and surrounding tumor cells through the crossfire effect.

Other names

yttrium Y 90 DOTA-peptide-Lym-1Y-90 DOTA-Lym-1 with peptide linkerY90 DOTA-Lym-1 with peptide linkerY 90 DOTA-Lym-1 with peptide linkerY-90 DOTA-peptide-Lym1Y90 DOTA-peptide-Lym1Y 90 DOTA-peptide-Lym1